Steps taken after granting the Marketing Authorisation 
For procedures finalised after 1 October 2002 please refer to module 8B. 
• 
The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  16  September  1997 
applications  for  two  type  I  variations  falling  within  the  scope  of  item  No.  17  (Change  in  the 
specification  of  the  medicinal  product)  and  item  No.  24  (Change  in  test  procedure  of  active 
substance)  of Annex I to  Commission  Regulation  (EC)  No  542/95. On 5 December  1997, the 
EMEA  approved  the  variations  (EMEA/H/C/125/I/01  and  EMEA/H/C/125/I/02).  These 
variations did not require amendments to the Commission Decision. 
• 
• 
• 
• 
• 
• 
The  Marketing  Authorisation  Holder  submitted  on  22  December  1997  a  request  to  change  the 
Labelling  and  the  Package  Leaflet  pursuant  to  Article 10(3)  of  Council  Directive  92/27/EEC  of 
31 March 1992. The EMEA sent the notification to the European Commission on 12 January 1998 
(EMEA/H/C/125/N/03).  The  Commission  decision  amending  the  Marketing  Authorisation  was 
issued on 3 March 1998.  
The Marketing Authorisation Holder submitted to the EMEA on 28 January 1998 an application 
for  one  type  I  variation  falling  within  the  scope  of  item  No  17  of  Annex  I  to  Commission 
Regulation  (EC)  No  542/95.  The  Marketing  Authorisation  Holder  applied  for  a  change  in 
specification of the medicinal product (inclusion of a specification for microbiological quality). 
On 4 March 1998, the EMEA approved the variation (EMEA/H/C/125/I/04). This variation did 
not require amendments to the Commission Decision. 
Pursuant to Article 13(2) of Council Regulation No. 2309/93 and Part 4G of the Annex to Council 
Directive  75/318/EEC,  the  Marketing  Authorisation  Holder  provided  throughout  the  year  of  the 
Marketing Authorisation additional efficacy and safety data as stated in Annex IIC to Commission 
Decision,  which  formed  the  basis  of  the  annual  re-assessment  of  the  benefit/risk  profile  of 
Cystagon. Data were provided on 22 June 1998 and completed on 14 October 1998 following the 
CPMP’s  request  during  its  plenary  session  on  15-17  September  1998.  The  Rapporteur’s  annual 
assessment report was circulated to all CPMP members on 7 December 1998. During its plenary 
meeting on 15-17 December 1998, the CPMP agreed with the Rapporteur’s assessment report that 
the  benefit/risk  of  mercaptamine  bitartrate  remained  favourable  and  that  the  Marketing 
Authorisation remains under exceptional circumstances. The CPMP opinion included a revised 
list  of  specific  obligations  of  Annex  II.C.  to  the  Community  Marketing  Authorisation 
(EMEA/H/C/125/S/05). The respective Commission Decision was issued on 19 April 1999. 
The Marketing Authorisation Holder submitted to the EMEA on 12 March 1999 an application 
for  one  type  I  variation  falling  within  the  scope  of  item  No  1  of  Annex  I  to  Commission 
Regulation  (EC)  No  542/95,  as  amended.  The  Marketing  Authorisation  Holder  applied  for  a 
change in the manufacturing site for part of the manufacturing process of the medicinal product. 
On 23 April 1999, the EMEA issued the corresponding notification (EMEA/H/C/125/I/06). This 
variation  required  amendments  to  annex  III  of  the  Community  Marketing  Authorisation.  The 
respective Commission Decision was issued on 01 July 1999. 
The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  10  May  1999  an  application 
for  three  type  I  variations  falling  within  the  scope  of  item  No  8,  14  and  24  of  Annex  I  to 
Commission  Regulation  (EC)  No  542/95,  as  amended.  The  Marketing  Authorisation  Holder 
applied  for  a  change  in  the  qualitative  composition  of  the  immediate  packaging  material,  a 
change  in  test  procedures  of  active  substance  and  a  change  in  specifications  of  the  active 
substance.  On  09  June  1999, 
the  corresponding  notifications 
(EMEA/H/C/125/I/07,  EMEA/H/C/125/I/08,  EMEA/H/C/125/I/09).  These  variations  did  not 
required  amendment  to  the  Community  Marketing  Authorisation.  The  respective  Commission 
Letter was issued on 18 June 1999. 
the  EMEA 
issued 
Pursuant to Article 13(2) of Council Regulation No. 2309/93 and Part 4G of the Annex to Council 
Directive 75/318/EEC, the Marketing Authorisation Holder provided throughout the second year of 
the  Marketing  Authorisation  additional  efficacy  and  safety  data  as  stated  in  Annex  IIC  to 
Commission  Decision,  which  formed  the  basis  of  the  annual  re-assessment  of  the  benefit/risk 
profile  of  Cystagon.  Data  were  provided  on  20  July  1999.  The  Rapporteur’s  annual  assessment 
1/3 
EMEA 2004 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
report was circulated to all CPMP members on 10 September 1999. During its plenary meeting on 
19-21 October 1999, the CPMP agreed with the Rapporteur’s assessment report that the benefit/risk 
of  mercaptamine  bitartrate  remained  favourable  and  that  the  Marketing  Authorisation  remains 
under  exceptional  circumstances.  The  CPMP  opinion  included  a  revised  list  of  specific 
obligations of Annex II.C. to the Community Marketing Authorisation (EMEA/H/C/125/S/11). 
The respective Commission Decision was issued on 16 March 2000. 
On  09  September  1999,  the  Marketing  Authorisation  Holder  submitted  a  Type  II  variation 
application  in  accordance  with  Article  6  of  Commission  Regulation  (EC)  No.  542/95  of  10 
March 1995, as amended. The scope of the variation related to the update of sections 4.2 and 4.9 
of the SPC following the CPMP’s assessments of first annual re-assessment and 2nd PSUR, and 
in section 5.3 following the fulfilment of a specific obligation. At this occasion, Annexes I, IIIA 
and  IIIB  have  been  updated  according  to  the  latest  EMEA/QRD  template.  On  18  November 
1999  the  CPMP  approved  the  variation  (EMEA/H/C/125/II/10).  The  variation  required 
amendments in the relevant sections of the Commission Decision and the EPAR. The European 
Commission amended the Decision on 16 March 2000. 
The  Marketing  Authorisation  Holder  submitted  on  12  January  2000  an  application  for  a  type  I 
variation falling within the scope of item No 14 of Annex I to Commission Regulation (EC) No 
542/95, as amended. The Marketing Authorisation Holder applied for a change in specification 
for  tartaric  acid  content  in  the  active  substance.  On  10  February  2000,  the  EMEA  issued  the 
corresponding notification (EMEA/H/C/125/I/12). This variation did not require amendments to 
the Commission Decision. 
The  Marketing  Authorisation  Holder  submitted  on  7  June  2000  an  application  for  a  type  I 
variation falling within the scope of item No 15a of Annex I to Commission Regulation (EC) 
No 542/95, as amended. The Marketing Authorisation Holder applied for a change in in-process 
controls applied during the manufacture of the product. On 14 July 2000, the EMEA issued the 
corresponding notification (EMEA/H/C/125/I/13). This variation did not require amendments to 
the Commission Decision. 
The Marketing Authorisation Holder submitted on 9 August 2000 an application for three type I 
variation  falling  within  the  scope  of  item  No  1  (change  in  the  premises  of  one  of  the 
manufacturing  sites  responsible  for  batch  release),  8  (change  in  quantitative  composition  of 
immediate  packaging  material)  and  32  (change  of  imprints)  of  Annex  I  to  Commission 
Regulation  (EC)  No  542/95,  as  amended.  On  21  September  2000,  the  EMEA  issued  the 
corresponding  notification  (EMEA/H/C/125/I/14,  EMEA/H/C/125/I/15,  EMEA/H/C/125/I/16). 
The variation No 1 requires amendments to Annexes II and IIIB of the Commission Decision. 
Pursuant to Article 13(2) of Council Regulation No. 2309/93 and Part 4G of the Annex to Council 
Directive 75/318/EEC, the Marketing Authorisation Holder provided throughout the third year of 
the Marketing Authorisation additional data as stated in Annex IIC to Commission Decision, which 
formed  the  basis  of  the  annual  re-assessment  of  the  benefit/risk  profile  of  Cystagon.  On  21 
September  2000,  the  CPMP,  having  reviewed  the  evidence  of  compliance  with  the  specific 
obligations  submitted  by  the  Marketing  Authorisation  Holder  and  having  re-assessed  the 
benefit/risk  profile  of  the  medicinal  product,  informed  the  European  Commission  that  no 
updating  of  Annex  I  and  III  to  the  Community  Marketing  Authorisation  for  the  medicinal 
product is required. The CPMP opinion included a revised list of specific obligations of Annex 
II.C.  to  the  Community  Marketing  Authorisation  (EMEA/H/C/125/S/17).  The  respective 
Commission Decision was issued on 29 January 2001. 
On  7  November  2000,  the  Marketing  Authorisation  Holder  submitted  a  Type  II  variation 
application  in  accordance  with  Article  6  of  Commission  Regulation  (EC)  No.  542/95  of  10 
March 1995, as amended. The scope of the variation related to the update of sections 4.3, 4.4, 
4.6, 5.1, 5.2 and 5.3 of the SPC in order to include new pharmacological data based on a recent 
clinical  pharmacokinetic  study  and  to  revise  the  information  on  pregnancy  based  on  new 
preclinical  data  on the reproduction toxicity of  the  active substance.  The latest QRD template 
has  also  been  taken  into  account  and  the  imprint  on  the  50  mg  capsule  has  been  corrected  in 
section 6.5. On 25 January 2001, the CPMP approved the variation (EMEA/H/C/125/II/18). The 
European Commission amended the Decision on 3 May 2001. 
2/3 
EMEA 2004 
 
 
 
 
 
• 
• 
On 23 February 2001, the Marketing Authorisation holder submitted an application for a type I 
variation  in  accordance  with  the  Commission  Regulation  (EC)  No  542/95,  as  amended.  The 
Marketing  Authorisation  Holder  applied  to  demonstrate  compliance  with  the  Commission 
Directive 1999/82/EC and the Note for Guidance on Minimising the risk of transmitting animal 
spongiform  Encephalopathy  agents  via  medicinal  products  (CPMP/BWP/1230/98),  and 
provided  certificates  of  suitability  issued  by  the  European  Pharmacopoeia  for  the  materials 
listed  in  Annex  B.  On  23  March  2001,  the  EMEA  issued  the  corresponding  notification 
(EMEA/H/C/125/I/19). This variation did not require amendments to the Commission Decision. 
Pursuant to Article 13(2) of Council Regulation No. 2309/93 and Part 4G of the Annex to Council 
Directive 75/318/EEC, the Marketing Authorisation Holder provided throughout the fourth year of 
the Marketing Authorisation additional data as stated in Annex IIC to Commission Decision, which 
formed the basis of the annual re-assessment of the benefit/risk profile of Cystagon. On 18 October 
2001,  the  CPMP,  having  reviewed  the  evidence  of  compliance  with  the  specific  obligations 
submitted by the Marketing Authorisation Holder and having re-assessed the benefit/risk profile 
of the medicinal product, informed the European Commission that no updating of Annex I and 
III to the Community Marketing Authorisation for the medicinal product is required. The CPMP 
opinion  included  a  revised  list  of  specific  obligations  of  Annex  II.C.  to  the  Community 
Marketing Authorisation (EMEA/H/C/125/S/20). 
3/3 
EMEA 2004 
 
 
 
 
 
